Prevalence of HCV among people who inject drugs in Brussels – A Respondent Driven Sampling Survey

Luk Van Baelen (✉ luk.vanbaelen@sciensano.be)
Sciensano  https://orcid.org/0000-0003-2119-7255

Els Plettinckx
Sciensano

Jérôme Antoine
Sciensano

Lies Gremeaux
Sciensano

Research

Keywords: People who inject drugs, hepatitis C, Belgium, prevalence

Posted Date: February 4th, 2020

DOI: https://doi.org/10.21203/rs.2.19102/v2

License: ☄️ ☀️ This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License

Version of Record: A version of this preprint was published at Harm Reduction Journal on February 21st, 2020. See the published version at https://doi.org/10.1186/s12954-020-00358-3.
Abstract

Background: In Belgium, people who inject drugs (PWID) are at a high risk of being infected by hepatitis C (HCV) as injecting drug use is the main mode for transmission of HCV in Europe. Estimates about the number of people living with HCV in Belgium are rare and even less is known about the prevalence of HCV among PWID.

Method: Between 1 February 2019 and 26 April 2019, PWID and high risk opiate users (HROU) were recruited in Brussels through respondent driven sampling (RDS). They were invited to a questionnaire and underwent a rapid HCV-test.

Results: 253 respondents participated in the study, of which 168 were PWID and 238 were HROU, with 153 respondents belonging to both categories. The overall unweighted sample average for HCV antibodies was 41.1%. The weighted population estimates were 43.7% (95%CI: 30.6% - 56.8%) for RDS-II and 43.4% (95%CI: 28.9% - 58.0%) for RDS-SS.

Conclusions: This prevalence is lower than the prevalence estimates reported elsewhere in Europe. However, the data still suggest that serious efforts are needed to reach the goal set by the WHO to reduce HCV by 2030 with 90%.

Background

Globally, an estimated 71 million people have a chronic hepatitis C virus (HCV) infection [1]. In the EU and Norway, the total number is estimated at 31,178 HCV cases for 2017. This corresponds to a crude rate of 7.3 cases per 100,000 population [2]. It is estimated that about 54–86% of those infected with HCV will develop chronic HCV [3]. Chronic HCV can lead to cirrhosis, hepatocellular carcinoma and premature death when it is not treated [1,4,5]. Infected persons do not show explicit symptoms of liver disease, but they are often tired, have poor appetite, nausea, muscle ache, etc. [4]. Consequently, a lot of people do not know that they are infected by the virus without undergoing a HCV screening [6]. Moreover, people can be re-infected with the same or different strains of the virus, even after a successful treatment [7]. Over the last 15 years, global mortality related to chronic HCV infection has steadily increased to over 400,000 deaths annually [1]. This contrasts with the declining number of deaths estimated from other infectious diseases such as HIV, tuberculosis and malaria [1], making HCV one of the main causes of chronic liver disease and mortality worldwide [8].

People who inject drugs (PWID) are at a high-risk of being infected by the virus [8,9] and injecting drug use is nowadays the main mode of HCV transmission [5]. The number of countries with studies quantifying the prevalence of HCV infection among PWID is increasing [10]. Globally, it is estimated that 10 million PWID are infected by HCV [8]. In addition, 23% of new HCV infections and one in three HCV deaths are attributable to injecting drug use [10]. In the EU and Norway, injecting drug use is reported as the likely cause for 40% of acute cases and 55% of chronic cases among the cases for which information
on the transmission mode is available [2]. During 2016-2017, HCV antibody prevalence ranged in Europe from 15% to 82% among PWID [11].

Estimates about the number of people living with HCV in Belgium are rare and even less is known about the prevalence of HCV among PWID [12]. We conducted a sero-behavioural study in Brussels among current PWID to obtain recent and accurate prevalence data of HCV.

**Methods**

Our formative research taught us that particularly for Brussels very few studies were done in the past among the PWID population. Based on expert opinions from key stakeholders including PWID and service providers, the PWID population in Brussels was estimated at between 500 and 1000, but apart from treatment centers and other community-based supportive groups there were no users groups of PWID and the connections between PWID were supposed to be weak. As standard probability methods are generally difficult to apply to hard-to-reach populations such as PWID [13] and because the hidden nature of injecting drug use decreased the potential for success of other survey strategies such as time-location sampling or simple random sampling, respondent driven sampling (RDS) was chosen as sampling method. It was decided to include also high-risk opiate users (HROU) in the study. They allowed us to reach PWID with a more diverse profile. The HROU, defined following the directives of the EMCDDA as people who used opiates at least once a week for six months in the last year without medical prescription [14], were seen as a bridge between different PWID sub-populations or individual PWID.

Between 1 February 2019 and 26 April 2019, we recruited PWID and HROU in Brussels using the RDS methodology. Eligibility criteria were: (i) self-reported injecting drug use in the last year and/or opiate use at least once a week for six months in the last year without medical prescription, (ii) aged 18 or older, (iii) having lived or used drugs in Brussels, (iv) having received a coupon from someone who participated already or being selected by one of the participating organizations, (v) willingness to answer to a questionnaire, (vi) willingness to undergo a rapid HCV-test and (vii) not having participated in the study before. Interviews were conducted in Dutch, French or English or in case of native Arabic and Russian speaking interviewers also in these two languages.

Sampling started with seven seeds, selected by low-threshold treatment centers or needle exchange programs in Brussels. Although seeds were selected for convenience, we encouraged diversity based on gender, age and mode of drug use as usual when applying RDS [15–17]. The recruitment followed the usual RDS sampling method of chain referral, where seeds recruited ‘first wave’ participants and ‘first wave’ participants recruited ‘second wave’ participants, and so on, until the end of the study period. Interviewers checked for track marks to verify recent injecting behavior. If marks were not found or the user confirmed no injecting practices, the subject had to demonstrate detailed acquaintance with opioid preparation for other modes of administration. At the end of the interview, every respondent received three recruitment coupons. The recruitment coupons were valid for one week, although expired coupons were not rejected in practice. The limitation of one week was mainly applied to encourage participants not to
wait too long before introducing the coupons to potential new participants. 90.4% of all participants arrived within this time limit. Because an adequate strategy on non-response or refusals was lacking, no further information is available on the actual response rate, i.e. the number of people who refused to participate. To ensure tracking of subsequent waves, the coupons had a unique identifying number to link the recruiter to the recruited person [18]. Each individual received €5 for participating in the interview and the HCV-test and €10 for each eligible participant they recruited, with a maximum of 3 new recruits per participant. To avoid doubles, we encoded individuals with their initials, sex and date of birth, and used custom-developed coupon manager software. If seeds turned out not to be productive or the recruitment stopped, we recruited additional seeds. With this strategy, we responded to poor recruitment during data collection without negatively impacting the theoretical and methodological requirements [19]. A team of multi-ethnic and multilingual nurses, conducted structured interviews and HCV-testing in a mobile unit. The interviews were immediately imputed in a questionnaire with all mandatory questions, developed in LimeSurvey [20] and saved on a central server. As a result the sample did not contain missing values.

During the study period, participants could come every day (7/7) between 17.00 and 21.00 to this mobile unit. Initially it was decided to park the mobile unit on fixed places, every day of the week another place where PWID could come and participate in the study and to repeat this patterns week after week. However, it turned out that the PWID were less mobile than expected and after ten days we changed the strategy and parked the mobile unit for several days in a row on a location known to PWID where we stayed until no new recruits arrived anymore. In total, people were interviewed and tested on nine different locations in the city.

At the onset of the interview, participants were informed about the study aims and were asked to sign a consent form. We asked questions on socio-demographic characteristics, drug use and injecting history, HCV risk behavior, previous HCV testing, previous and current HCV treatment, previous and current drug use treatment, number of overdoses, network size and the relationship with their recruiter. To distinguish between respondents who were rather in contact with PWID and others who were more in contact with HROU, network size was defined as (i) “How many people in Brussels who have injected opiates such as heroin, morphine, opium or fentanyl in the last 6 months do you know by name who know your name?”, (ii) “How many people in Brussels who have used opiates such as heroin, morphine, opium or fentanyl without prescription and without injecting and who have injected drugs in the last 6 months but not opiates do you know by their name who know your name?”, (iii) “How many people in Brussels who have injected drugs in the last 6 months but not opiates do you know by their name who know your name?” or (iv) “How many people in Brussels who have used opiates such as heroin, morphine, opium or fentanyl without medical prescription without injecting in the last 6 months do you know by their name who know your name?”. The questionnaire was pre-tested and based on the Drug Related Infectious Disease toolkit, developed by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) [21], the WHO guidelines for RDS [22], the Belgian HIV register (for the unique person’s identifier) [23], with some additional questions from the Australian national drug strategy household survey [24,25] and a HIV/HCV risk behavior survey from Yale University [26]. Prevalence of HCV was tested with the whole blood InTec Rapid HCV antibody Test. We did not have the possibility to confirm HCV antibody positive results with a
PCR HCV RNA test as recommended by the national guidelines [6]. Respondents were offered pre- and post-counselling according to national and international guidelines [6].

Based on the aforementioned estimated number of PWID in Brussels and with an estimated HCV-prevalence of 40% [27], a CI of 95%, z=1.96, a design effect of 1.5 [1] and a standard error of 0.05, we reached a sample size on which we applied a finite population correction [28], resulting in a required sample size of 269 PWID. Seeds were included in every part of the analysis. Selection bias was examined for age and sex by comparing the participants’ profile with the profile of patients in low-threshold treatment centers and needle exchange programs in Brussels and within the sample through t-tests and χ²-tests.

RDSAT version 7.1.46 was used to verify the stability of the study sample. The homophily metric (Hx) was between −1 and 1, with Hx < −0.3 and Hx > 0.3 used for the identification of significant biases, as is conventional in RDS analysis [18,29]. We used RStudio version 1.1.442, package ‘RDS’ [30] to calculate equilibrium for sex, mean age and HCV prevalence, which was attained when the sample distribution from one recruitment wave to the next fell within a discrepancy of less than 2% [28]. For respondents who answered that their personal network size was 0, degree values were imputed using the weighted mean of the non-missing degrees, calculated with Gile’s SS [30]. Since there is no consensus on which estimator is optimal [31], we give the unweighted sample average for HCV antibody prevalence among PWID as well as the RDS-II and RDS-SS weighted estimate. We did the graphical representation of the complete network in NetDraw version 2.160. For reasons of completeness, descriptive statistics for HROU will be presented as well. The reporting of this study conforms to the STROBE guidelines for RDS studies [32].

**Results**

Ultimately, 256 people were considered eligible, consented and were recruited. The RDS chain referral started with 7 seeds, with an additional 14 seeds who were selected when recruitment stopped. Seeds were mainly men (95.2%), living in Brussels (95.2%), having a median age of 42 and a negative HCV antibody status (57.1%). In addition, two eligible recruits were selected by a respondent who was not eligible and one participant managed to refer four new respondents instead of the allowed three. We decided to keep the data for these three additional participants as separate seeds, which gives an overall number of 24 seeds. These 24 seeds recruited 229 eligible respondents, which result in a total of 253 respondents and a response proportion of 30%. Fifteen seeds resulted in at least one wave of new participants. Two seeds resulted in the two longest chains that were together responsible for the participation of 172 respondents or 68% of all respondents. In total, we have an average of 3.3 waves per seed (± SD 3.2, median 2, range 1-11). Three respondents managed to participate twice, which was discovered only after the interview took place. The data for their second participation were excluded from the analysis and they did not recruit any new respondents. Of the 253 respondents, 168 were PWID and 238 were HROU, with 153 respondents belonging to both categories. The recruitment chains are presented in figure 1. After three months, the targeted community of PWID and HROU in Brussels was saturated.
For HCV antibody prevalence and age the number of waves required for equilibrium was five, whereas for recent injecting behavior and sex it was nine. Homophily among participants was overall positive, except for female respondents (Hx=-0.27) and respondents who were HCV antibody positive (Hx=-0.01).

Recruitment weights for the full sample ranged between 0.93 and 1.08 for age, 0.98 and 1.23 for sex, 0.99 and 1.15 for recent non-prescribed opioid use, 0.98 and 1.01 for recent injecting behavior and 0.96 and 1.02 for HCV antibody status.

The overall unweighted sample average for HCV antibodies was 41.1%. The weighted population estimates were 43.7% (95%CI 30.6% - 56.8%) for RDS-II and 43.4% (95%CI 28.9% - 58.0%) for RDS-SS. As shown in table 1, PWID were mostly male (90.5%) and living in Brussels (92.9%), with a median age of 40 years. When comparing the PWIDs’ profile with the profile of patients in low-threshold treatment centers and needle exchange programs in Brussels, age did not significantly differ (t=-0.45, p=0.65). However, we had a lower proportion of women in the sample compared to patients known to the established structures ($\chi^2=6.2, p=0.013$). Indeed, the sample only contained 9.5% female PWID, whereas the other structures had between 17.8% and 18.5% women. Among PWID in the sample, there were no significant differences between men and women for age (t=-0.31, p=0.76), injection of heroin ($\chi^2=0.13, p=0.94$), injection of cocaine ($\chi^2=1.7, p=0.2$), recruiter ($\chi^2=6.2, p=0.18$) or other variables of interest. However, the unweighted sample average for HCV antibody for female PWID was 81.3% (95%CI 57.0%-93.4%), whereas the unweighted HCV antibody sample estimate for male PWID was 36.8% (95%CI 29.6%-44.7%) ($\chi^2=10.03, p=0.002$).

Most PWID injected heroin (75.6%), cocaine (82.1%) or other opiates (33.3%) in the last year. In addition, 91.1% of the PWID used not-prescribed opiates at least once a week for 6 months in the last 12 months. Almost three in four reported to have ever received opioid substitution treatment (76.8%), while among them 71.3% were currently in opioid substitution treatment. Most PWID had been tested in the past for HCV (62.5%), and among them, 52.4% reported a positive test result. Only 21 respondents, or 38.2% from those who said they were infected with HCV, reported they had been treated for HCV in the past.

The relationship between recruiters and recruit was as follows: 41.1% of the respondents was recruited by a friend, 35.1% by an acquaintance with whom they were not close and 10.1% by a stranger. The reported network size ranged from 0 to 1000 individuals, with an average of 37 ($\pm$ SD 120.6, median 10). Other additional information which is not shown in table 1: out of 159 PWID who had used non-prescribed opiates in the last year, 32 (or 20%) reported an overdose due to opiates. Out of 146 recent PWID who reported previous or current treatment for their drug use, only 97 (or 66.4%) said they had been tested for HCV before, whereas out of 20 ever PWID who reported previous or current treatment for their drug use, 17 (or 85%) said they had been tested for HCV before. Recent HCV risk behavior (last 30 days) related to sharing injection equipment among PWID ranged between 25.6% (using rinse water that somebody else had used before) and 54.8% (having split drugs with other persons).

As shown in table 2, for PWID who tested positive for HCV antibodies the odds were higher when they were female, they had already injected other opiates than heroin, they had been tested before for HCV and
they were on substitution treatment. Interestingly, drawing a shot from a cooker in the past 30 days that was used by someone else before, decreased the odds for a positive HCV antibody result, although this result was only slightly statistically significant and might be an artefact. In that case, there would be no association between recent risk behavior and a positive HCV antibody test result.

**Discussion**

In the Brussels context, the recruitment strategy through RDS turned out to be useful to collect data among PWID and HROU. Although almost all of the PWID reported regular use of not-prescribed opiates in the last year, this study reached a substantial proportion of PWID (45.2%) who were currently not on opiate substitution treatment. Also, 35.1% of the PWID indicated to have never been tested for HCV before.

The study gives important results about HCV among PWID. Firstly, approximately 43% of the PWID in Brussels tested positive for HCV antibodies. This prevalence is lower compared to prevalence estimates reported in Europe. According to a European systematic review in 2014 [5], the median number of positive HCV antibodies among PWID tested for HCV in Europe was 82.9% (IQR 59%–100%), and figures for 2019 reported that in eight out of the 14 countries in Europe with national data, more than half of the PWID have been infected with HCV [11]. The lower prevalence in Brussels might be the result of considerable efforts to reduce harms among PWID. In Brussels, there are 5 needle exchange programs on 7 locations and additionally, pharmacies are involved in the distribution of kits at the cost of 0.5 euro, containing two syringes, two alcohol swabs, two dry post-injecting swabs, two spoons, two flasks of injectable sterile water and harm reduction information. These programs already exists for more than 20 years in Brussels.

Secondly, previous research in Belgium found that 86.5% of recent PWID and 84.7% of ever PWID in treatment between 2011 and 2014 were tested for HCV between 2008 and 2015 [12]. In the current study, only 66.4% of recent PWID who reported previous or current treatment for their drug use, said they had been tested for HCV before. This is much lower than the results from the previous study indicated [12]. However, 85% of ever PWID who reported previous or current treatment for their drug use said they had been tested for HCV before, which corresponds to what was found in the previous study [12]. These results could indicate that the recent PWID in the current study were much earlier in their drug career than the recent PWID in the previous study and that PWID have to spend some time in treatment before they are tested for HCV. As described in previous research, the lack of knowledge and incorrect assumptions among health professionals working with this population can hamper successful HCV diagnoses and treatment [33,34].

It is also important to mention the limitations of this study. Firstly, although the results clearly indicate that HCV is endemic among the study population, this study does not provide evidence about whether HCV is attributed to drug use rather than sex-related or other behavior [9]. Indeed, the data are not appropriate for determining what led to the HCV infection. For example, recent risk behavior (last 30 days) did not increase the odds for a positive HCV antibody result. Only characteristics which indicate a longer
injection career such as being on substitution treatment or having been tested before on HCV, as well as being female and having injected other opiates than heroin in the last 12 months increased the odds for a positive test result. However, based on this information it remains unclear what caused the HCV infection.

Secondly, because of budgetary and logistical constraints, we could not reach the required sample size of 269. Given the small total PWID population in Brussels, we have tried to overcome this weakness by comparing the characteristics for the sample with the profile of PWID in other databases from treatment centers and a crisis intervention center in Brussels. However, we cannot exclude that some subpopulations were not included in the final sample. For example, notwithstanding tremendous efforts, we could not reach a recruitment chain of people who intentionally use and inject drugs to have sex – chemsex – among men who have sex with men. In addition, some Arab- and Russian-speaking PWID dropped out because they wanted to participate at a moment when there was no interviewer available who spoke their language. Finally, the RDS sampling method resulted in a lower proportion of women compared to female PWID known to the established structures in Brussels. The female PWID in the current study tested significantly more positive on HCV antibodies than the male respondents. A systematic review and meta-analysis of 28 studies published globally found an overall higher risk of HCV infection of 36% for female PWID compared to male PWID [35]. Since the profile of these women in the current study did not vary significantly from men for other variables, it is necessary to study the behavioral or structural factors contributing to sex related differences more in detail in future research.

We could mention two potential explanations for the lower proportion of women. Firstly, sampling bias might be the reason, although it remains unclear why. Secondly, it might be that women find their way to treatment centers more easily than men and they are overrepresented in established drug related structures compared to their presence in the street. Previous research shows for example that women search more actively for health-related information [36] and visit more often health-care providers for physical but also mental health concerns compared to men [37,38]. For men, stigma has a more deterrent effect on help seeking compared to women [37,39].

In conclusion, firstly, the current study shows results for the prevalence of HCV which are below the European average, but the data still suggest that serious efforts are needed to reach the goal set by the WHO to reduce HCV by 2030 with 90% [40]. Secondly, RDS turned out to be very useful to reach PWID at the beginning of their drug career who were not yet in contact with treatment centers and who had not yet been tested.

**Abbreviations**

PWID: People Who Inject Drugs; HROU: High-risk Opiate Users; HCV: Hepatitis C; HCVab: Hepatitis C antibodies; EMCDDA: European Monitoring Centre for Drugs and Drugs Addiction; RDS: Respondent Driven Sampling; CI: Confidence Interval; Hx: homophily metric;

**Declarations**
Ethics approval and consent to participate

All participants consented in writing before participating. The study protocol was approved by the commission for medical ethics of University hospital Ghent (Nr B670201837344).

Consent for publication

Not applicable

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

No funding to declare.

Authors’ contributions

LVB designed the study, did the fieldwork, analyzed the data and wrote the first draft of the paper. EP did the fieldwork and was a major contributor in writing the manuscript. JA was the major link with the local partners and supported the fieldwork. LG supervised the study. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to thank Prof. R. Heimer and Prof. F. Crawford (Yale University) for their support in the design and the analysis of the study. They also thank the local partners Transit asbl, MASS/MSOC Brussels, Projet Lama and SamuSocial for their support in reaching out for PWID. A special thanks to all the nurses who conducted the fieldwork and who had a major contribution in the success of the study. Last but not least thanks to all the participants for their confidence and time.

References

1. World Health Organization (WHO). Access to hepatitis C testing and treatment for people who inject drugs and people in prisons - a global perspective. Policy brief. Geneva: World Health Organization; 2019.

2. ECDC.Annual epidemiological report for 2017. Hepatitis C. 2019;
3. Mathel C, Wollants E, Verbeeck J, Van Ranst M, Robaey G, Van Damme P, et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. European Journal of Clinical Microbiology and Infectious Diseases. 2005;24:514–22.

4. Micalessi I, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. Journal of medical virology. 2008;80:640–5.

5. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C Virus Infection Epidemiology among People Who Inject Drugs in Europe: A Systematic Review of Data for Scaling Up Treatment and Prevention. PLOS ONE. 2014;9:e103345.

6. Agentschap Zorg & Gezondheid. Richtlijnen Infectiebestrijding Vlaanderen - Hepatitis C [Internet]. 2017 Jan. Available from: _https://www.zorg-en-gezondheid.be/sites/default/files/atoms/files/Richtlijn%20Hepatitis%20C_2017.pdf_

7. Matheï C, Van Dooren S, Lemey P, Van Damme P, Buntinx F, Vandamme AM. The epidemic history of hepatitis C among injecting drug users in Flanders, Belgium. J Viral Hepat. 2008;15:399–408.

8. Bielen R, Moreno C, Van Vlierberghe H, Bourgeois S, Mulkay JP, Vanwollehgem T, et al. Belgian experience with direct acting antivirals in people who inject drugs. Drug and alcohol dependence. 2017;177:214–20.

9. Scheinmann R, Hagan H, Lelutiu-Weinberger C, Stern R, Des Jarlais DC, Flom PL, et al. Non-injection drug use and Hepatitis C Virus: a systematic review. Drug and Alcohol Dependence. 2007;2006/12/15:1–12.

10. Degenhardt L, Peacock A, Colledge S, Leung J, Grebely J, Vickerman P, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. The Lancet Global Health. 2017;5:e1192–207.

11. EMCDDA. Drug-related infectious diseases in Europe: update from the EMCDDA expert network. Lisbon: EMCDDA; 2019.

12. Van Baelen L, Antoine J, De Ridder K, Muyldermans G, Gremeaux L. Diagnostic hepatitis C testing of people in treatment for substance use disorders in Belgium between 2011 and 2014: a cross-sectional study. Acta Gastroenterol Belg. 2019;82:35–42.

13. Wenz B, Nielsen S, Gassowski M, Santos-Hövener C, Cai W, Ross RS, et al. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011–14). BMC Public Health. 2016;16:927.

14. Thanki D, Vicente J. PDU (Problem drug use) revision summary [Internet]. EMCDDA; 2013 [cited 2020 Jan 22]. Available from: http://www.emcdda.europa.eu/attachements.cfm/att_218205_EN_PDU%20revision.pdf
15. Wu J, Crawford FW, Raag M, Heimer R, Uusküla A. Using data from respondent-driven sampling studies to estimate the number of people who inject drugs: Application to the Kohtla-Järve region of Estonia. PLoS One. 2017;12:e0185711–e0185711.
16. Wang J, Carlson RG, Falck RS, Siegel HA, Rahman A, Li L. Respondent-driven sampling to recruit MDMA users: a methodological assessment. Drug and Alcohol Dependence. 2005;78:147–57.
17. Weinert C. SOCIAL NETWORK ANALYSIS WITH RESPONDENT-DRIVEN SAMPLING DATA: A STUDY OF RACIAL INTEGRATION ON CAMPUS. Soc Networks. 2010;32:112–24.
18. Heckathorn DD. Respondent-Driven Sampling: A New Approach to the Study of Hidden Populations. Social Problems. 1997;44:174–99.
19. Uusküla A, Johnston LG, Raag M, Trummal A, Talu A, Des Jarlais DC. Evaluating recruitment among female sex workers and injecting drug users at risk for HIV using respondent-driven sampling in Estonia. J Urban Health. 2010;2010/02/04:304–17.
20. LimeSurvey Project Team / Carsten Schmitz. LimeSurvey: An Open Source survey tool. LimeSurvey Project: Hamburg, Germany; 2012.
21. EMCDDA. DRID Guidance Module: Example questionnaire for bio-behavioural surveys in people who inject drugs. Lisbon: EMCDDA; 2013.
22. World Health Organization (WHO). Introduction to HIV/AIDS and sexually transmitted infection surveillance: Module 4: Introduction to respondent-driven sampling. WHO - Regional Office for the Eastern Mediterranean; 2013.
23. Sasse A Defraye A. HIV-infecties en AIDS in België. Vlaams Infectieziektenbulletin. 2008;65:8–12.
24. Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2001: detailed findings. Canberra: Australian Institute of Health and Welfare; 2002.
25. Australian Institute of Health and Welfare. National Drug Strategy Household Survey 2016: detailed findings. Canberra: Australian Institute of Health and Welfare; 2017.
26. Heimer R, Bink M, Koester S, Grund J-PC, Patel A, Paintsil E, et al. Recovery of Infectious Hepatitis C Virus From Injection Paraphernalia: Implications for Prevention Programs Serving People Who Inject Drugs. J Infect Dis. 2018;217:466–73.
27. Mathéi C; Bourgeois S; Blach S; Brixko C; Mulkay JP; Razavi H; Robaeys G. Mitigating the burden of hepatitis C virus among people who inject drugs in Belgium. Acta Gastroenterol Belg. 2016;79:227–32.
28. Weinert C. An Empirical Test of Respondent-Driven Sampling: Point Estimates, Variance, Degree Measures, and Out-of-Equilibrium Data. Sociol Methodol. 2009;39:73–116.
29. Heckathorn DD. Respondent-Driven Sampling II: Deriving Valid Population Estimates from Chain-Referral Samples of Hidden Populations. Social Problems. 2002;49:11–34.
30. Handcock M. FI Gile K. RDS: Respondent-Driven Sampling, Version 0.9-0. Los Angeles, CA; 2012.
31. Wirtz AL, Mehta SH, Latkin C, Zelaya CE, Galai N, Peryshkina A, et al. Comparison of Respondent Driven Sampling Estimators to Determine HIV Prevalence and Population Characteristics among
Men Who Have Sex with Men in Moscow, Russia. PLOS ONE. 2016;11:e0155519–e0155519.

32. White RG, Hakim AJ, Salganik MJ, Spiller MW, Johnston LG, Kerr L, et al. Strengthening the Reporting of Observational Studies in Epidemiology for respondent-driven sampling studies: “STROBE-RDS” statement. J Clin Epidemiol. 2015;2015/05/01:1463–71.

33. Foster GR. Injecting drug users with chronic hepatitis C: should they be offered antiviral therapy? Addiction. 2008;103:1412–3.

34. Higgs P, Sacks-Davis R, Gold J, Hellard M. Barriers to receiving hepatitis C treatment for people who inject drugs: Myths and evidence. Hepatitis Monthly. 2011;11:513–8.

35. Esmaeili A, Mirzazadeh A, Carter GM, Esmaeili A, Hajarizadeh B, Sacks HS, et al. Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis. J Viral Hepat. 2017;2016/10/28:117–27.

36. Ek S. Gender differences in health information behaviour: a Finnish population-based survey. Health Promotion International. 2013;30:736–45.

37. Vogel DL, Wester SR, Hammer JH, Downing-Matibag TM. Referring men to seek help: The influence of gender role conflict and stigma. Psychology of Men & Masculinity. 2014;15:60–7.

38. Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Family Practice. 2016;17:38.

39. Clement S, Schauman O, Graham T, Maggioni F, Evans-Lacko S, Bezborodovs N, et al. What is the impact of mental health-related stigma on help-seeking? A systematic review of quantitative and qualitative studies. Psychological Medicine. 2015;2014/02/21:11–27.

40. World Health Organization (WHO). Combating hepatitis B and C to reach elimination by 2030. Geneva, Switzerland; 2016.

Tables

Table 1. Descriptive statistics for PWID and HROU in Brussels, 2019
| Age (mean ± sd, median, range) | PWID and HROU (a) | PWID non-HROU (b) | Non-PWID HROU (c) | Total PWID (a)+(b) | Total HROU (a)+(c) |
|-------------------------------|-------------------|-------------------|-------------------|-------------------|-------------------|
|                               | 40.5±9.5, 40, 20-65 | 37.0±8.6, 34, 23-52 | 41.7±9.2, 45, 19-65 | 40.1±9.4, 40, 20-65 | 40.9±9.4, 42, 19-65 |
| Sex                           |                   |                   |                   |                   |                   |
| Male                          | 139 (90.9)        | 13 (86.7)         | 80 (94.1)         | 152 (90.5)        | 219 (92.0)        |
| Female                        | 14 (9.2)          | 2 (13.3)          | 5 (5.9)           | 16 (9.5)          | 19 (8.0)          |
| Place of residence            |                   |                   |                   |                   |                   |
| In Brussels                   | 145 (94.8)        | 11 (73.3)         | 82 (96.5)         | 156 (92.9)        | 227 (95.4)        |
| Not in Brussels               | 8 (5.2)           | 4 (26.7)          | 3 (3.5)           | 12 (7.1)          | 11 (4.6)          |
| Use of not-prescribed opiates at least once a week for 6 months in the last 12 months | Yes |                   |                   |                   |                   |
|                               | 0 (0.0)           | 15 (100.0)        | 0 (0.0)           | 15 (8.9)          | 0 (0.0)           |
|                               | No                |                   |                   |                   |                   |
| Injected any drug in the last 12 months | Yes | 153 (100.0)      | 15 (100.0)        | 0 (0.0)           | 168 (100.0)       | 153 (64.3)        |
|                               | No                | 0 (0.0)           | 0 (0.0)           | 85 (100.0)        | 0 (0.0)           | 85 (35.7)         |
| Injected heroin in the last 12 months | Yes | 120 (78.4)       | 7 (46.7)          | 0 (0.0)           | 127 (75.6)        | 120 (50.4)        |
|                               | No                | 33 (21.6)         | 8 (53.3)          | 85 (100.0)        | 41 (24.4)         | 118 (49.6)        |
| Injected cocaine in the last 12 months | Yes | 125 (81.7)       | 13 (86.7)         | 0 (0.0)           | 138 (82.1)        | 125 (52.5)        |
|                               | No                | 28 (18.3)         | 2 (13.3)          | 85 (100.0)        | 30 (17.9)         | 113 (47.5)        |
| Injected other opiates in the last 12 months | Yes | 54 (35.3)        | 2 (13.3)          | 0 (0.0)           | 56 (33.3)         | 54 (22.7)         |
|                               | No                | 99 (64.7)         | 13 (86.7)         | 85 (100.0)        | 112 (66.7)        | 184 (77.3)        |
| Injected amphetamines in the last 12 months | Yes | 21 (13.7)        | 6 (40.0)          | 0 (0.0)           | 27 (16.1)         | 21 (8.8)          |
|                               | No                | 132 (86.3)        | 9 (60.0)          | 85 (100.0)        | 141 (83.9)        | 217 (91.2)        |
| Injected NPS in the last 12 months | Yes | 9 (5.9)          | 0 (0.0)           | 0 (0.0)           | 9 (5.4)           | 9 (3.8)           |
|                               | No                | 144 (94.1)        | 15 (100.0)        | 85 (100.0)        | 159 (94.6)        | 229 (96.2)        |
| Injected other drugs in the last 12 months | Yes | 6 (3.9)          | 1 (6.7)           | 0 (0.0)           | 7 (4.2)           | 6 (2.5)           |
|                               | No                | 147 (96.1)        | 14 (93.3)         | 85 (100.0)        | 161 (95.8)        | 232 (97.5)        |
| Ever tested on HCV            | Yes               |                   |                   |                   |                   |
|                               | 98 (64.1)         | 7 (46.7)          | 47 (55.3)         | 105 (62.5)        | 145 (60.9)        |
|                               | Infected          | 51 (52.0)         | 4 (57.1)          | 8 (17.0)          | 55 (52.4)         | 59 (40.7)         |
|                               | Not infected      | 43 (43.9)         | 2 (28.6)          | 37 (82.7)         | 45 (42.9)         | 80 (55.2)         |
|                               | Don't know        | 4 (4.1)           | 1 (14.3)          | 2 (4.3)           | 5 (4.8)           | 6 (4.1)           |
|                               | No                | 51 (33.3)         | 8 (53.3)          | 28 (32.9)         | 59 (35.1)         | 79 (33.2)         |
|                               | Don't know        | 4 (4.1)           | 0 (0.0)           | 10 (11.8)         | 4 (2.4)           | 14 (5.9)          |
|                                | Yes       | No       | Don't know | Total   |
|--------------------------------|-----------|----------|------------|---------|
| Ever in treatment for HCV (only for those who were tested and infected) | 20 39.2 1 25.0 3 37.5 | 31 60.8 3 75.0 5 62.5 | 0 0.0 1 12.5 24 0 | 153 100 15 100 85 100 |
| Ever in substitution treatment | 120 78.4 9 60.0 60 70.6 | 33 27.5 4 44.4 17 28.3 | 0 0.0 0 0.0 1 1.2 | 168 100 15 100 85 100 |
|                                | Now       | Before   |            |         |
|                                | 87 72.5 5 55.6 43 71.7 | 33 27.5 4 44.4 17 28.3 |            |         |
| Ever in other drug related treatment | 120 78.4 9 60.0 60 70.6 | 33 27.5 4 44.4 17 28.3 | 0 0.0 0 0.0 1 1.2 | 168 100 15 100 85 100 |
|                                | Now       | Before   |            |         |
|                                | 82 53.6 8 53.3 36 42.4 | 64 78.0 8 100.0 31 86.1 |            |         |
| Referral                       | Stranger  | Acquaintance but not close | Friend | Partner |
|                                | 14 9.2 3 20.0 11 12.9 | 54 35.3 5 33.3 33 38.8 | 63 41.2 6 40.0 18 21.2 | 6 3.9 0 0.0 2 2.4 |
|                                | 0 0.0 0 0.0 0 0.0 | 0 0.0 0 0.0 0 0.0 | 0 0.0 0 0.0 0 0.0 | 1 0.7 0 0.0 0 0.0 |
|                                | Total     | Total    |            |         |
|                                | 153 100 15 100 85 100 | 168 100 15 100 85 100 |            |         |
| Risk behavior (past 30 days)   | split drugs with someone else | used a syringe that had been used before | injected drugs that were mixed, measured or divided up with a used syringe | draw a shot from someone else's cooker | draw a shot from someone else's water | used rinse water from somebody else |
|                                | 85 55.6 7 46.7 0 0.0 | 40 26.1 5 33.3 0 0.0 | 72 47.1 6 40.0 0 0.0 | 72 22.9 7 46.7 0 0.0 | 39 25.5 4 26.7 0 0.0 |
|                                | 78 46.4 72 47.1 | 45 26.8 40 26.1 | 79 47.0 72 47.1 | 72 22.9 7 46.7 0 0.0 | 43 25.6 39 25.5 |
| HCV anti-body test             | Positive  | Negative |            |         |
|                                | 66 43.1 3 20.0 14 16.5 | 87 56.9 12 80.0 71 83.5 |            |         |
|                                | 69 41.1 80 33.6 | 99 58.9 158 66.4 |            |         |
| Total                          | 153 100 15 100 85 100 | 168 100 15 100 85 100 |            |         |
|                                | Estimate | SE  | z   | Odds ratio (95%CI) |
|--------------------------------|----------|-----|-----|--------------------|
| (Intercept)                    | 1.52     | 1.08| 1.42| 4.59 (0.56 – 37.89) |
| not used heroin in the past 12 months (vs used heroin) | -1.53   | 1.03| -1.49| 0.22 (0.03 – 1.63) |
| female (vs male)               | 2.10     | 0.84| 2.49| 8.17 (1.57 – 42.6) |
| never injected heroin (vs injected) | -0.72   | 0.84| -0.85| 0.49 (0.09 – 2.54) |
| never injected other opiates (vs injected) | -1.74   | 0.51| -3.38| 0.18 (0.06 – 0.48) |
| never injected amphetamines (vs injected) | -0.86   | 0.56| -1.54| 0.42 (0.14 – 1.26) |
| never injected cocaine (vs cocaine) | 0.74    | 1.07| 0.69| 2.1 (0.26 – 17.01) |

in the past 30 days

| split drugs with someone else (vs not split drugs) | -0.39  | 0.57 | -0.68| 0.68 (0.22 – 2.08) |
| used a syringe that had been used before (vs not used syringe) | 1.45   | 0.88 | 1.65| 4.25 (0.76 – 23.84) |
| injected drugs that were mixed, measured or divided up with a used syringe (vs not mixed, measured or divided up with a used syringe) | 0.55   | 0.85 | 0.65| 1.73 (0.33 – 9.09) |
| draw a shot from someone else's cooker (vs not draw shot from other cooker) | -1.79  | 0.82 | -2.18| 0.17 (0.03 – 0.83) |
| draw a shot from someone else's water (vs not draw shot from other's water) | -0.10  | 0.80 | -0.13| 0.9 (0.19 – 4.3) |
| used rinse water from somebody else (vs not used other's rinse water) | 0.52   | 0.71 | 0.73| 1.68 (0.42 – 6.76) |
|                              | Estimate | SE  | z value | Odds ratio (95%CI) |
|------------------------------|----------|-----|---------|-------------------|
| not tested for HCV before (vs tested for HCV before) | -1.98    | 0.56| -3.52   | 0.14 (0.05 – 0.42) |
| not on substitution treatment (vs on substitution treatment) | -2.33    | 0.70| -3.34   | 0.1 (0.02 – 0.38)  |
| not on other drug treatment (vs on other drug treatment) | 0.84     | 0.48| 1.75    | 2.33 (0.91 – 5.97) |

Table 2
Regression estimates, standard error (SE), z-value and odds ratios for PWID having tested positive on the HCVab test in Brussels, 2019

Figures
Legend:
Red: Seed – Blue: Wave
Square: PWID – Round: Non-PWID
Bold: HCVab+ - Not bold: HCVab-

Figure 1

Recruitment chains of RDS in Brussels, 2019